Back to top
more

Intercept Pharmaceuticals, Inc. (ICPT)

(Delayed Data from NSDQ)

$89.92 USD

89.92
705,568

+1.71 (1.94%)

Updated May 3, 2019 04:00 PM ET

After-Market: $89.98 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Biotech Stock Roundup: REGN's Stake Buyback, INO, NVAX's Coronavirus Updates & More

by Zacks Equity Research

The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.

Zacks.com headshot

Intercept Down on Postponement of AdCom Meet for NASH Drug

by Zacks.com

The FDA defers advisory committee meeting date pertaining to Intercept's (ICPT) NDA for obeticholic acid to treat liver fibrosis due to nonalcoholic steatohepatitis.

Intercept's (ICPT) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Intercept (ICPT) reports better-than-expected results for the first quarter of 2020 on solid Ocaliva sales.

Intercept Pharmaceuticals (ICPT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Intercept (ICPT) delivered earnings and revenue surprises of 2.72% and 6.42%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Yash Killa headshot

Is Intercept (ICPT) Stock a Solid Choice Right Now?

by Yash Killa

Intercept (ICPT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Is Intercept (ICPT) Down 30.9% Since Last Earnings Report?

by Zacks Equity Research

Intercept (ICPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Intercept (ICPT) Q4 Earnings Miss, Revenues Beat Estimates

by Zacks Equity Research

Intercept (ICPT) incurs wider loss in the fourth quarter while sales top mark. Shares fall probably as the action date for OCA's NDA to treat fibrosis due to NASH gets extended by the FDA.

Intercept Pharmaceuticals (ICPT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Intercept (ICPT) delivered earnings and revenue surprises of -16.80% and 4.36%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Intercept (ICPT) Concludes Enrollment in Study on NASH Drug

by Zacks Equity Research

Intercept (ICPT) closes enrollment in late-stage study evaluating obeticholic acid for the treatment of compensated cirrhosis due to nonalcoholic steatohepatitis.

Gilead (GILD) Announces Top-Line Results From NASH Study

by Zacks Equity Research

Gilead's (GILD) mid-stage study on combination and monotherapy investigational treatments for advanced fibrosis due to NASH fails to meet the primary endpoint.

Intercept (ICPT) Up 48.6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Intercept (ICPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Intercept (ICPT) Gains 7.5% YTD on Progress in NASH Space

by Zacks Equity Research

Intercept (ICPT) stock gains as it becomes the forerunner in the NASH drug race.

The Zacks Analyst Blog Highlights: Intercept, CymaBay, Amgen, Global Blood Therapeutics and ChemoCentryx

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Intercept, CymaBay, Amgen, Global Blood Therapeutics and ChemoCentryx

Ekta Bagri headshot

NASH Scorecard Year to Date: The Winners and the Losers

by Ekta Bagri

NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.

Biotech Stock Roundup: CBAY Falls, CCXI Gains, Amgen Acquires Otezla & More

by Zacks Equity Research

Key highlights of the past week include regulatory and pipeline updates.

Company News For Nov 26, 2019

by Zacks Equity Research

Companies In The News Are:

Intercept's (ICPT) NDA for NASH Drug Gets Priority Review

by Zacks Equity Research

Intercept (ICPT) obtains Priority Review for its NDA for OCA in the United States for the treatment of fibrosis due to NASH.

Intercept (ICPT) Earnings and Sales Miss Estimates in Q3

by Zacks Equity Research

Intercept (ICPT) reports a wider-than-expected loss and misses on sales in the third quarter of 2019.

Intercept Pharmaceuticals (ICPT) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Intercept (ICPT) delivered earnings and revenue surprises of -10.21% and -2.32%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Intercept Pharmaceuticals (ICPT) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Intercept (ICPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Enanta's Stock Down Despite NASH Drug Meeting Goal in Study

by Zacks Equity Research

Enanta (ENTA) posts favorable top-line data from the phase IIa study on its pipeline candidate EDP-305 for treating NASH. Albeit the study meets its goals, the stock declines in after-hours trading.

Why Is Intercept (ICPT) Down 2.5% Since Last Earnings Report?

by Zacks Equity Research

Intercept (ICPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Intercept (ICPT) Q2 Earnings & Sales Beat, NASH in Focus

by Zacks Equity Research

Intercept (ICPT) posts a narrower-than-expected loss in Q2 and surpasses sales estimates.

Intercept Pharmaceuticals (ICPT) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Intercept (ICPT) delivered earnings and revenue surprises of 9.16% and 12.21%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Will Intercept Pharmaceuticals (ICPT) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

Intercept (ICPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.